US EditionRadiation or Immune-Modulating Drugs Could Mitigate Resistance to CDK4/6 Inhibitors in Breast Cancer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
The Institute of Research of Hcor (Hospital do Cora o), in S Paulo, gave in this regard a study cl nico which seeks to check the effect of the creabel or, t breast-feeding of the mother's breast, compared conventional surgery in the treatment of the tumor mam rio em est initial joy. The institution established the voluntary search rias for research at 15 August. Read more (07/09/2025)
New Insights Reveal How Cancer’s Microenvironment Impacts CDK4/6 Inhibitor Effectiveness – Patient Worthy
Recent research outlined by Medical Xpress offers a deeper understanding of why CDK4/6 inhibitors, a class of drugs widely used to treat certain cancers, sometimes fail to deliver lasting benefits. The findings highlight the crucial role of the tumor microenvironment—the surrounding non-cancerous cells and molecules—in influencing how cancer cells respond to these targeted therapies. CDK4/6 […]
TP53 Missense-Specific Transcriptional Plasticity Drives Resistance against Cell Cycle Inhibitors in Pancreatic Cancer
Integrating multicenter patient data and multi-omics, scientists reported that the misp53R273H/C mutant is associated with cell cycle progression and a basal-like state compared to the misp53R248W/Q mutant. [Science Advances] Full Article
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
